前梯度蛋白2(AGR2)檢測(cè)試劑盒DIY材料(酶聯(lián)免疫吸附試驗(yàn)法)
ELISA Kit DIY Materials for Anterior Gradient 2 (AGR2)
GOB4; HAG2; XAG2; AG2; PDIA17; HPC8; Anterior Gradient Protein 2; Protein Disulfide Isomerase Family A,Member 17; Secreted cement gland protein XAG-2 homolog
- 編號(hào)KSC285Ra01
- 物種Rattus norvegicus (Rat，大鼠)相同的名稱，不同的物種。
- 試劑內(nèi)容包被抗體、檢測(cè)抗體、標(biāo)準(zhǔn)品、HRP標(biāo)記的鏈霉親和素、TMB底物、96孔板
- 可檢測(cè)樣本Serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids.
- 可適用原理雙抗夾心酶聯(lián)免疫吸附試驗(yàn)法測(cè)抗原
- 可檢測(cè)范圍1.56-100ng/mL
- 可適靈敏度0.62ng/mL
- 應(yīng)用自己動(dòng)手制作ELISA試劑盒的主要材料
- 下載英文說(shuō)明書 中文說(shuō)明書
- 規(guī)格96T*596T*1096T*2096T*5096T*100
- 價(jià)格¥ 7423¥ 12372¥ 22270¥ 43302¥ 74232
- 欲了解實(shí)際交易價(jià)格和更多情況，請(qǐng)與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
產(chǎn)品包裝(模擬)
產(chǎn)品包裝(模擬)
通過(guò)ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
試劑盒中的抗體對(duì)前梯度蛋白2(AGR2)具有高靈敏度和高特異性，經(jīng)檢測(cè)與其它相似物質(zhì)無(wú)明顯交叉反應(yīng)。
用法
1.用100μL每孔的工作濃度的包被抗體包被96孔板，4度孵育過(guò)夜或者37度孵育2小時(shí)；
2.洗板1次；
3.用200μL每孔的工作濃度的封閉液,37度孵育1.5小時(shí)；
4.洗板1次。酶標(biāo)板即可用于ELISA實(shí)驗(yàn)，后續(xù)使用方法與ELISA同。
儲(chǔ)存
抗體，標(biāo)準(zhǔn)品和HRP標(biāo)記的鏈霉親和素在-20度保存，TMB需在4度保存，96孔板在室溫保存。所有組分保質(zhì)期為1年，試劑一旦開封，在4度保存時(shí)間為1個(gè)月。
配套試劑
贈(zèng)品
增值服務(wù)
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種：Rattus norvegicus (Rat，大鼠) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| RPC285Ra01 | 前梯度蛋白2(AGR2)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAC285Ra01 | 前梯度蛋白2(AGR2)多克隆抗體 | IHC |
| LAC285Ra71 | 前梯度蛋白2(AGR2)多克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
| MAC285Ra22 | 前梯度蛋白2(AGR2)單克隆抗體 | IHC |
| MAC285Ra23 | 前梯度蛋白2(AGR2)單克隆抗體 | WB |
| MAC285Ra26 | 前梯度蛋白2(AGR2)單克隆抗體 | WB; IHC; ICC; IP. |
| MAC285Ra21 | 前梯度蛋白2(AGR2)單克隆抗體 | IHC |
| MAC285Ra24 | 前梯度蛋白2(AGR2)單克隆抗體 | WB; IHC; ICC; IP. |
| MAC285Ra27 | 前梯度蛋白2(AGR2)單克隆抗體 | IHC |
| MAC285Ra25 | 前梯度蛋白2(AGR2)單克隆抗體 | IHC |
| KSC285Ra01 | 前梯度蛋白2(AGR2)檢測(cè)試劑盒DIY材料(酶聯(lián)免疫吸附試驗(yàn)法) | 自己動(dòng)手制作ELISA試劑盒的主要材料 |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| Cancer Biomarkers | Serum AGR2 as an early diagnostic and postoperative prognostic biomarker of human lung adenocarcinoma[MetaPress: n7137r6271u54118] |
| Molecular & Cellular Proteomics | Integrated Proteomic Profiling of Cell Line Conditioned Media and Pancreatic Juice for the Identification of Pancreatic Cancer Biomarkers[PubMed: PMC3205865] |
| Prostate. | Anterior gradient 2 (AGR2): blood-based biomarker elevated in metastatic prostate cancer associated with the neuroendocrine phenotype[Pubmed: 22911164] |
| BMC Cancer. | Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9[Pubmed: 24007603] |
| Clinical Cancer Research | Validation of Biomarkers That Complement CA19.9 in Detecting Early Pancreatic Cancer[Pubmed:25239611] |
| PLoS One | AGR3 in Breast Cancer: Prognostic Impact and Suitable Serum-Based Biomarker for Early Cancer Detection[PubMed: 25875093] |
| Clinical Neurology and Neurosurgery | Serum AGR2 as a useful biomarker for pituitary adenomas[S0303846717300045] |
| Oncotarget | Identification, characterization and application of a new peptide against anterior gradient homolog 2 (AGR2)[Pubmed:29937991] |
| Int J Oncol | Anterior gradient protein 2 is a marker of tumor aggressiveness in breast cancer and favors chemotherapy?induced senescence escape[34913074] |
| International Journal of Cancer | Proteome profiling of enzalutamide‐resistant cell lines and serum analysis identified ALCAM as marker of resistance in castration‐resistant prostate cancer[Pubmed:35689436] |